Cardiac resynchronization therapy market analysis (2026–2030)
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Cardiac Resynchronization Therapy Market Over The 2026–2030 Period?
The cardiac resynchronization therapy market has seen significant expansion in recent years. It is projected to increase from $6.72 billion in 2025 to $7.18 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. Historically, this growth has been fueled by factors such as the increasing prevalence of heart failure, improved awareness of ventricular dyssynchrony, the expansion of cardiac device implantation centers, advancements in pacemaker technology, and growing clinical evidence supporting crt benefits.
The cardiac resynchronization therapy market is anticipated to experience substantial expansion over the upcoming years, projected to reach $8.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. This projected growth is driven by several factors, including a heightened demand for advanced CRT systems, the increasing acceptance of remote management solutions for cardiac devices, a burgeoning elderly population suffering from heart failure, a greater emphasis on enhancing therapeutic effectiveness, and a rise in capital expenditure within cardiac rhythm management technologies. Key developments anticipated during this period encompass a greater uptake of sophisticated CRT devices, an increase in personalized device programming, the wider incorporation of remote device monitoring, the spread of less invasive implantation methods, and a stronger emphasis on maximizing patient outcomes.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Key Factors Are Driving The Cardiac Resynchronization Therapy Market Growth?
The expanding occurrence of cardiovascular diseases is anticipated to boost the expansion of the Cardiac Resynchronization Therapy Market in the coming years. Cardiovascular diseases (CVD) are conditions impacting the heart and blood vessels. The rise in cardiovascular disease is attributed to several elements, such as an aging demographic, unhealthy routines, increased tobacco consumption, inactive habits, and insufficient nutrition. Cardiac resynchronization therapy (CRT) aids conditions like heart failure by enhancing the synchronization of heart contractions via the transmission of timed electrical impulses. For example, in September 2024, data released by the Minnesota Department of Health, a US-based state health agency, indicated that about 30% of adults in Minnesota reported elevated blood pressure in 2023, amounting to nearly 1.4 million individuals. Furthermore, in 2022, hypertensive conditions were the primary or secondary cause of death for 14,225 inhabitants, making up almost 28% of all fatalities in the state. Consequently, the growing incidence of cardiovascular diseases is fueling the growth of the Cardiac Resynchronization Therapy Market.
Which Segment Types Are Examined In The Cardiac Resynchronization Therapy Market Segment Study?
The cardiac resynchronization therapy market covered in this report is segmented –
1) By Type: Cardiac Resynchronization Therapy (CRT)-Defibrillator, Cardiac Resynchronization Therapy (CRT)-Pacemaker
2) By Age: Below 44 Years, 45-64 Years, 65-84 Years, Above 85 Years
3) By End-Use: Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers
Subsegments:
1) By Cardiac Resynchronization Therapy (CRT)-Defibrillator: Single-Chamber CRT-D, Dual-Chamber CRT-D, Triple-Chamber CRT-D, Bi-Ventricular CRT-D
2) By Cardiac Resynchronization Therapy (CRT)-Pacemaker: Single-Chamber CRT-P, Dual-Chamber CRT-P, Triple-Chamber CRT-P, Bi-Ventricular CRT-P
Which Trends Are Guiding The Direction Of The Cardiac Resynchronization Therapy Market?
Companies operating in the cardiac resynchronization therapy market are concentrated on developing implantable devices, including cardiac Resynchronization Therapy Device Launch, to enhance real-time hemodynamic optimization and achieve better patient-specific cardiac pacing outcomes. A Cardiac Resynchronization Therapy (CRT) Device Launch denotes the official release of an implantable medical device engineered to improve the timing of heart chamber contractions in individuals with heart failure. For example, in February 2024, MicroPort Scientific Corporation, a China-based medical device enterprise, introduced the GALI SonR cardiac resynchronization therapy and defibrillation device (CRT-D), an implantable device, and the Navigo 4LV left ventricular pacing leads in Japan. This device is noteworthy as the pioneering and sole CRT hemodynamic sensor designed to automatically optimize patients weekly, and crucially, during patient activity, facilitating real-life optimization. The clinically proven SonR algorithm has demonstrated a 35% reduction in the risk of heart failure hospitalization and is expected to contribute to the well-being and safety of the CRT-D patient.
Which Players Are Part Of The Competitive Landscape Of The Cardiac Resynchronization Therapy Market?
Major companies operating in the cardiac resynchronization therapy market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co KG, MicroPort Scientific Corporation, LivaNova PLC, Lepu Medical Technology Beijing Co Ltd, Osypka Medical GmbH, EBR Systems Inc, Japan Lifeline Co Ltd, CCC Medical Devices, Shree Pacetronix Ltd, BPL Medical Technologies, Medico Srl, Pacetronix, Lepu Healthcare, Blue Cross Bio Medical, Cardiac Science International, Beijing Jinshi Medical, Suzhou Medical Instrument Factory
Get The Full Cardiac Resynchronization Therapy Market Report:
Which Region Represents The Largest Share Of The Cardiac Resynchronization Therapy Market?
North America was the largest region in the cardiac resynchronization therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cardiac Resynchronization Therapy Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Cardiac Resynchronization Therapy Market 2026, By The Business Research Company
Implantable Heart Pacemaker Market Report 2026
https://www.thebusinessresearchcompany.com/report/implantable-heart-pacemaker-global-market-report
Heart Blocks Treatment Devices Market Report 2026
Cardiac Pacemakers Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
